The Oncoguard® Liver test was designed to deliver a high level of accuracy with enhanced sensitivity for detection of early-stage HCC.1
Robustly designed for early detection of HCC in real-world settings
At 87% specificity, the Oncoguard® Liver test demonstrates:
Validation of the test demonstrated high performance compared with:
Ongoing clinical trials
Learn more about the clinical trials the Oncoguard® Liver solution is currently engaged in.
Survival rates for patients with HCC are improved with early-stage detection
Localized stage
60-70%
Five-year survival rate for those who are diagnosed at an early stage and undergo curative therapy
Distant stage
3-12%
Five-year survival rate for those diagnosed at late stage2
The Oncoguard® Liver solution. Exactly what’s needed today.
Learn more about the scientific rigor behind the Oncoguard® Liver test.
References: 1. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, Clinical Gastroenterology and Hepatology (2021), doi: https:// doi.org/10.1016/j.cgh.2021.08.010 2. Liver cancer survival rates. American Cancer Society. Revised January 29, 2021. Accessed March 23, 2021. https://www.cancer.org/cancer/liver-cancer/detection-diagnosis-staging/survival-rates.html.